ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för eltoprazine. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

21 träffar

Bibliografisk träff 2024-08-13

Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a Drosophila Model of Fragile X Syndrome.

Vannelli A, Mariano V, Bagni C, Kanellopoulos AK.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms25168787

Bibliografisk träff 2023-04-30

Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.

Bi Y, Wang P, Yu J, Wang Z, Yang H, Deng Y, Guan J, Zhang W.

CNS Neurosci Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/cns.14241

Bibliografisk träff 2021-07-03

Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist.

Pinna A, Costa G, Serra M, Contu L, Morelli M.

Neuropharmacology · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neuropharm.2021.108693

Bibliografisk träff 2019-01-03

Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate.

Wang Q, Chen J, Li M, Lv S, Xie Z, Li N, Wang N, Wang J, Luo F, Zhang W.

Neuropharmacology · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1016/j.neuropharm.2018.12.027

Bibliografisk träff 2017-07-21

A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.

Ko WKD, Li Q, Cheng LY, Morelli M, Carta M, Bezard E.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2017.07.030

Bibliografisk träff 2017-01-01

Further pharmacological characterization of eltoprazine: focus on its anxiolytic, anorexic, and adverse‑effect potential.

Gravius A, Dekundy A, Vanaga A, Franke L, Danysz W.

Acta Neurobiol Exp (Wars) · journal article · DOI 10.21307/ane-2017-038

Bibliografisk träff 2016-11-17

The 5-HT1A/1B-receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in the nucleus accumbens and decreases motivation for reward and "waiting" impulsivity, but increases "stopping" impulsivity.

Korte SM, Prins J, Van den Bergh FS, Oosting RS, Dupree R, Korte-Bouws GA, Westphal KG, Olivier B, Denys DA, Garland A, Güntürkün O.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2016.11.024

Bibliografisk träff 2016-02-12

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M.

Mov Disord · research support, non-u.s. gov't; journal article · DOI 10.1002/mds.26475

Bibliografisk träff 2016-01-08

On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.

Carta M, Cenci MA.

Mov Disord · letter; research support, non-u.s. gov't · DOI 10.1002/mds.26519

Bibliografisk träff 2015-11-27

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.

Ghiglieri V, Mineo D, Vannelli A, Cacace F, Mancini M, Pendolino V, Napolitano F, di Maio A, Mellone M, Stanic J, Tronci E, Fidalgo C, Stancampiano R, Carta M, Calabresi P, Gardoni F, Usiello A, Picconi B.

Neurobiol Dis · research support, non-u.s. gov't; journal article · DOI 10.1016/j.nbd.2015.11.022

Bibliografisk träff 2015-07-24

Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.

Paolone G, Brugnoli A, Arcuri L, Mercatelli D, Morari M.

Mov Disord · research support, non-u.s. gov't; journal article · DOI 10.1002/mds.26326

Bibliografisk träff 2015-06-25

Effect of selective and non-selective serotonin receptor activation on L-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats.

Tronci E, Fidalgo C, Stancampiano R, Carta M.

Behav Brain Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbr.2015.06.034

Bibliografisk träff 2015-02-10

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.

Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Björklund A, Widner H.

Brain · clinical trial, phase ii; research support, non-u.s. gov't; research-article; clinical trial, phase i; randomized controlled trial; journal article · DOI 10.1093/brain/awu409

Bibliografisk träff 2013-02-06

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.

Bezard E, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Mov Disord · research support, non-u.s. gov't; journal article · DOI 10.1002/mds.25366

Bibliografisk träff 2011-05-06

Pharmacokinetic evaluation of eltoprazine.

Wigal SB, Duong S.

Expert Opin Drug Metab Toxicol · review; journal article · DOI 10.1517/17425255.2011.580275

Bibliografisk träff 1999-10-01

Discriminative stimulus properties of eltoprazine in the pigeon.

Olivier B, Herremans A, Mos J, van Drimmelen M, Tulp M, van Oorschot R, Hijzen T.

Pharmacol Biochem Behav · journal article · DOI 10.1016/s0091-3057(99)00073-8

Bibliografisk träff 1997-01-01

Discriminative stimulus properties of eltoprazine.

Gommans J, Hijzen TH, Maes RA, Olivier B.

Life Sci · journal article · DOI 10.1016/s0024-3205(97)00352-4

Bibliografisk träff 1995-10-01

A series of N4-imidoethyl derivatives of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine as 5-HT1A receptor ligands: synthesis and structure-affinity relationships.

van Steen BJ, van Wijngaarden I, Tulp MT, Soudijn W.

J Med Chem · journal article · DOI 10.1021/jm00021a020

Bibliografisk träff 1995-09-01

Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines.

Peglion JL, Canton H, Bervoets K, Audinot V, Brocco M, Gobert A, Le Marouille-Girardon S, Millan MJ.

J Med Chem · journal article · DOI 10.1021/jm00020a020

Bibliografisk träff 1990-10-01

The actions of the novel anti-aggressive drug eltoprazine on central neurones in the anaesthetised rat.

Evans SM, Girdlestone D, Lopez A, Olivier B, Roberts MH.

Neuropharmacology · journal article · DOI 10.1016/0028-3908(90)90139-i

Bibliografisk träff 1990-04-01

Eltoprazine suppresses hyperpolarizing responses to serotonin in rat hippocampus.

Joëls M, Pennartz CM, Sijbesma H, Schipper J.

J Pharmacol Exp Ther · journal article · DOI 10.1016/s0022-3565(25)12457-9

Gå till forskningen.

Publikationer i urvalet

Activation of the 5-HT1A Receptor by Eltoprazine Restores Mitochondrial and Motor Deficits in a <i>Drosophila</i> Model of Fragile X Syndrome.

Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.

Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT<sub>1A/1B</sub> receptor agonist and A<sub>2A</sub> receptor antagonist.

Eltoprazine prevents levodopa-induced dyskinesias by reducing causal interactions for theta oscillations in the dorsolateral striatum and substantia nigra pars reticulate.

A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.

Further pharmacological characterization of eltoprazine: focus on its anxiolytic, anorexic, and adverse‑effect potential.

The 5-HT<sub>1A/1B</sub>-receptor agonist eltoprazine increases both catecholamine release in the prefrontal cortex and dopamine release in the nucleus accumbens and decreases motivation for reward and "waiting" impulsivity, but increases "stopping" impulsivity.

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.

On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.

Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.

Effect of selective and non-selective serotonin receptor activation on L-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats.

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.

Pharmacokinetic evaluation of eltoprazine.

Discriminative stimulus properties of eltoprazine in the pigeon.

Discriminative stimulus properties of eltoprazine.

A series of N4-imidoethyl derivatives of 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine as 5-HT1A receptor ligands: synthesis and structure-affinity relationships.

Characterization of potent and selective antagonists at postsynaptic 5-HT1A receptors in a series of N4-substituted arylpiperazines.

The actions of the novel anti-aggressive drug eltoprazine on central neurones in the anaesthetised rat.

Eltoprazine suppresses hyperpolarizing responses to serotonin in rat hippocampus.